Valeant Adds Eyetech’s Macugen To Ophthalmic Portfolio
This article was originally published in The Pink Sheet Daily
The acquisitive Canadian specialty pharma’s latest deal is a relatively small one, giving it a wet AMD treatment that lags behind Lucentis and other newcomers.
You may also be interested in...
Ophthotech, OncoMed, and bluebird bio are three of the dozens of biotechs that have made public debuts this year. Here’s how they did it, and the decisions they made to take advantage of being in the right place at the right time.
NICE has given the thumbs-up to Bayer’s Eylea in wet AMD, but its impressive cost-effectiveness could spell trouble for Novartis’ Lucentis in the long run.
As with its Medicis buyout in 2012, Valeant is acquiring another company to serve essentially as a therapeutic division within the specialty pharma the Canadian firm is cobbling together from relentless M&A activity. Buying B&L will increase Valeant’s eye care holdings substantially.